Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. (abre una nueva ventana)

Barillari G, Pasca S, Barillari A, De Angelis V.

Fuente‎: Blood Transfus 2012;10(1):87-94.

Indexado en‎: PubMed 22044952

DOI‎: 10.2450/2011.0030-11

https://www.ncbi.nlm.nih.gov/pubmed/22044952 (abre una nueva ventana)

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (abre una nueva ventana)

Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R; American College of Chest Physicians.

Fuente‎: Chest 2012;141(2 Suppl):e326S-50S.

Indexado en‎: PubMed 22315266

DOI‎: 10.1378/chest.11-2298

https://www.ncbi.nlm.nih.gov/pubmed/22315266 (abre una nueva ventana)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (abre una nueva ventana)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Fuente‎: Lancet 2015;385(9982):2077-87.

Indexado en‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (abre una nueva ventana)

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. (abre una nueva ventana)

Hanke AA, Joch C, Görlinger K.

Fuente‎: Br J Anaesth 2013;110(5):764-72.

Indexado en‎: PubMed 23335567

DOI‎: 10.1093/bja/aes501

https://www.ncbi.nlm.nih.gov/pubmed/23335567 (abre una nueva ventana)

Emergency reversal of warfarin anticoagulation. (abre una nueva ventana)

Lin Y, Callum J.

Fuente‎: CMAJ 2010;182(18):2004.

Indexado en‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (abre una nueva ventana)

Recent advances in the development of specific antidotes for target-specific oral anticoagulants. (abre una nueva ventana)

Mo Y, Yam FK.

Fuente‎: Pharmacotherapy 2015;35(2):198-207.

Indexado en‎: PubMed 25644580

DOI‎: 10.1002/phar.1532

https://www.ncbi.nlm.nih.gov/pubmed/25644580 (abre una nueva ventana)

Idarucizumab for dabigatran reversal - full cohort analysis. (abre una nueva ventana)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Fuente‎: N Engl J Med 2017;377(5):431-41.

Indexado en‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (abre una nueva ventana)

Oral anticoagulation in surgical procedures: risks and recommendations. (abre una nueva ventana)

Torn M, Rosendaal FR.

Fuente‎: Br J Haematol 2003;123(4):676-82.

Indexado en‎: PubMed 14616972

https://www.ncbi.nlm.nih.gov/pubmed/14616972 (abre una nueva ventana)